---
title: 'JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17
  cells: Final Phase II Trial Results'
date: '2024-07-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39046783/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240724182556&v=2.18.0.post9+e462414
source: Blood
description: 'Our phase I graft-versus-host disease (GVHD) prevention trial of JAK2
  inhibitor, pacritinib, (recommended phase II dose: 100mg po BID day 0 to +70) plus
  sirolimus and tacrolimus (PAC/SIR/TAC) demonstrated the regimen was safe and free
  of pan-JAK myelosuppression after allogeneic hematopoietic cell transplantation
  (alloHCT). PAC inhibits IL-6 receptor activity and pathogenic Th1/Th17 differentiation
  in preclinical models and the phase I trial. Herein we report on our completed phase
  II trial ...'
disable_comments: true
---
Our phase I graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib, (recommended phase II dose: 100mg po BID day 0 to +70) plus sirolimus and tacrolimus (PAC/SIR/TAC) demonstrated the regimen was safe and free of pan-JAK myelosuppression after allogeneic hematopoietic cell transplantation (alloHCT). PAC inhibits IL-6 receptor activity and pathogenic Th1/Th17 differentiation in preclinical models and the phase I trial. Herein we report on our completed phase II trial ...